Galectin Therapeutics CMO sells shares post option exercise
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 per share and sold 16,250 shares at a weighted average price of $5.1252 on July 14, 2026, under a Rule 10b5-1 trading plan.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 per share and sold 16,250 shares at a weighted average price of $5.1252 on July 14, 2026, under a Rule 10b5-1 trading plan. Following the derivative transaction, he held 48,750 stock options.
Insider Trade Summary 10b5-1
Exercise and Sale: 16,250 shares ($34K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Jamil Khurram
Role
Chief Medical Officer
Sold
16,250 shs ($83K)
Approx. gross sale proceeds
$83K
Approx. exercise cost
$49K
Approx. pre-tax spread
$34K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F1, F3 | 16,250 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 16,250 | $3.04 | $49K |
| Sale | Common Stock F1, F2 | 16,250 | $5.1252 | $83K |
Holdings After Transaction:
Stock option (right to buy) — 48,750 options (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026
- F2. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3. The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027.
Key Figures
Common shares sold: 16,250 shares
Weighted average sale price: $5.1252 per share
Options exercised: 16,250 options
+3 more
6 metrics
Common shares sold
16,250 shares
Open-market sale by Chief Medical Officer on July 14, 2026
Weighted average sale price
$5.1252 per share
Average price for multiple sale transactions on July 14, 2026
Options exercised
16,250 options
Stock options exercised and converted into common shares on July 14, 2026
Option exercise price
$3.04 per share
Exercise or conversion price for stock options exercised
Remaining stock options
48,750 options
Stock options (right to buy) held after the reported transactions
Option expiration date
January 16, 2036
Expiration date of the stock option (right to buy) position
Key Terms
Rule 10b5-1 plan, weighted average sale price, derivative security, Stock option (right to buy)
4 terms
Rule 10b5-1 plan regulatory
"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"This amount represents the weighted average sale price of such transactions"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Stock option (right to buy) financial
"Stock option (right to buy)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did GALT's Chief Medical Officer report?
Jamil Khurram, CMO of Galectin Therapeutics (GALT), reported exercising stock options for 16,250 shares at $3.04 and selling 16,250 common shares on July 14, 2026. The sale and exercise occurred as part of his equity compensation activity.
What stock options did the GALT CMO exercise in this Form 4 filing?
Khurram exercised 16,250 stock options, each with an exercise price of $3.04, converting them into common shares. A footnote explains the option grant vests in four equal tranches of 16,250 options on specific dates through December 31, 2027.
Were the GALT insider's stock sales made under a Rule 10b5-1 plan?
Yes. A footnote states the transaction was made pursuant to a Rule 10b5-1 plan adopted by Jamil Khurram on February 2, 2026. The plan’s adoption date was previously disclosed in Galectin Therapeutics’ Quarterly Report on Form 10-Q filed on May 15, 2026.
How many Galectin Therapeutics options does Jamil Khurram hold after these transactions?
Following the reported option exercise, Khurram held 48,750 stock options (right to buy) in Galectin Therapeutics. These options have an exercise price of $3.04 per share and an expiration date of January 16, 2036, according to the derivative transaction disclosure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
